IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML

Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and the BM stroma is a major mechanism underlying therapy resistance in AML. Lenali...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Millan, Belen, Diaz de la Guardia, Rafael, Roca-Ho, Heleia, Anguita, Eduardo, Islam, Abul B. M. M. K., Romero-Moya, Damia, Prieto, Cristina, Gutierrez-Agüera, Francisco, Bejarano-Garcia, Jose Antonio, Perez-Simon, Jose Antonio, Costales, Paula, Rovira, Montse, Marín, Pedro, Menendez, Silvia, Iglesias, Mar, Fuster, Jose Luis, Urbano-Ispizua, Alvaro, Anjos-Afonso, Fernando, Bueno, Clara, Menendez, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140592/
https://www.ncbi.nlm.nih.gov/pubmed/30228947
http://dx.doi.org/10.1080/2162402X.2018.1477460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140592/
https://www.ncbi.nlm.nih.gov/pubmed/30228947
http://dx.doi.org/10.1080/2162402X.2018.1477460

Ejemplares similares